Sociedad Americana de Hirudoterapia

MS-proteomics provides insight into the host responses towards alginate microspheres

Research article published in Materials today. Bio (2022)

Última actualización: 18 de junio de 2026Revisado por: ASH Editorial Board
Artículo de investigación — revisión de evidenciaReferencia del artículo
Evidence: Research reportGenómica y proteómicaCoron AE et al. · Materials today. Bio, 2022

Abstract

Protein adsorption to biomaterial surfaces is considered a determining factor for the host response. Here we detail the protein adsorption profiles of alginate hydrogel microspheres relevant for cell therapy using mass spectrometry (MS)-based proteomics. The investigated microspheres include sulfated alginate (SA), high G alginate (HiG), and poly-l-lysine coated alginate (AP), which previously have been shown to exhibit different inflammatory and fibrotic responses. The biological significance was assessed in lepirudin-anticoagulated human whole blood (hWB) by functional analysis of the acute-phase responses (complement and coagulation). Proteomic profiling revealed distinct signatures for the microspheres, wherein Ingenuity Pathway Analysis identified complement and coagulation as the top enriched canonical pathways. The levels of complement and coagulation activators and inhibitors were distinctly different, which was reflected in the functional hWB analyses: SA was highly enriched with inhibitory factors of complement and coagulation (e.g. C1 inhibitor, factor H, antithrombin-III, heparin cofactor 2), other heparin-binding proteins and factors promoting fibrinolysis (factor XII, plasma kallikrein), conforming to an anti-inflammatory and anti-fibrotic profile. HiG enriched moderate levels of complement inhibitors, conforming to a low-inflammatory and pro-fibrotic profile. AP showed the most prominent enrichment of complement activators (e.g. C3, properdin, C-reactive protein) and low levels of inhibitors, conforming to a pro-inflammatory and highly pro-fibrotic profile. In conclusion, the extensive enrichment of inhibitory acute-phase proteins on SA could be a determining factor for its reduced host response. The interactions between the plasma proteins and hydrogel surfaces shown herein point to proteomics as an important supplement to existing in vitro and in vivo methods for designing biocompatible alginate-based hydrogels.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal Article

Resumen

Protein adsorption to biomaterial surfaces is considered a determining factor for the host response.

Por qué esto importa para la hirudoterapia

Este estudio empleó proteómica basada en espectrometría de masas para caracterizar los perfiles de adsorción proteica de microesferas de hidrogel de alginato (alginato sulfatado, alginato con alto contenido de ácido gulurónico, alginato recubierto con poli-L-lisina) y evaluó las respuestas funcionales de fase aguda en sangre humana total anticoagulada con lepirudina. Firmas distintivas de enriquecimiento de proteínas del complemento y de la coagulación correspondieron al perfil inflamatorio y fibrótico de cada microesfera, enriqueciendo el alginato sulfatado factores inhibidores. La relevancia de la lepirudina/hirudina se limita a su papel como anticoagulante de investigación que permite ensayos funcionales de complemento/coagulación. Salvedad: no participan sanguijuelas ni la hirudoterapia; la lepirudina sirvió únicamente como herramienta anticoagulante, y el estudio aborda las respuestas del huésped al biomaterial, no terapéuticos derivados de la sanguijuela.

Citación

MS-proteomics provides insight into the host responses towards alginate microspheres

Coron AE et al. · Materials today. Bio, 2022

Contexto clínico relacionado

Añadido a la biblioteca ASH: May 27, 2026 · Última actualización del sitio: 18 de junio de 2026

Este sitio web proporciona información educativa y no constituye consejo médico, diagnóstico ni recomendaciones de tratamiento. La terapia con sanguijuelas medicinales conlleva riesgos clínicamente significativos y debe ser realizada únicamente por profesionales calificados bajo protocolos aprobados institucionalmente. La autorización 510(k) de la FDA para sanguijuelas medicinales se limita a indicaciones específicas; las discusiones sobre uso investigativo y fuera de indicación se señalan correspondientemente. Para orientación médica específica, consulte a un profesional de salud calificado.